Mercator Medical Group, a manufacturer of disposable gloves and distributor of medical materials, generated PLN 145.6 million in sales revenue in the first quarter of 2026, according to preliminary estimates. This means the Group maintained a stable level of sales compared with the same period last year.
Consolidated EBITDA reached PLN 15.4 million, representing an increase of 185% compared with PLN 5.4 million a year earlier. The Group’s net profit amounted to PLN 12.9 million. The significant difference in net profit compared with the same period in 2025 was mainly due to the surplus of positive foreign exchange differences over negative ones.
In the first quarter, the medical gloves market operated in conditions of elevated volatility caused by geopolitical factors and disruptions in global supply chains. From Mercator Medical Group’s perspective, this required flexible management of production, purchasing, inventories and sales directions between Asia, Europe and the United States.
“The Group continuously analyses the market and adjusts its operational and sales activities to changing conditions. Operational resilience, supply diversification and the development of higher value-added products are of key importance, including the premium segment and solutions responding to growing regulatory and environmental requirements. Despite high volatility and uncertainty in the market, we maintained a stable level of revenue year on year, while higher margins translated into a better EBITDA result,” said Mariusz Popek, Member of the Management Board of Mercator Medical S.A.
According to the published estimates, the Group’s consolidated net profit in the January–March period amounted to PLN 12.9 million, compared with PLN 30.3 million in net profit in the same period of 2025.
The significant difference in net profit between the first quarters of 2025 and 2026 results mainly from the surplus of positive foreign exchange differences over negative ones recognised in financial income. This surplus amounted to PLN 19.4 million in the first quarter of last year, compared with PLN 0.9 million in the first quarter of 2026.
Thanks to its stable financial position, Mercator Medical Group is able to implement its development strategy and key investments. At the end of March 2026, the Group had approximately PLN 204 million in net cash and other financial assets.
The figures presented are preliminary and estimated. The consolidated and separate financial statements for the first quarter of 2026 are currently being prepared, with publication of the results scheduled for 1 June 2026.
